시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 POC(Point of Care) 감염증 검사 시장 보고서(2025년)
Point Of Care Infectious Disease Testing Global Market Report 2025
상품코드 : 1760696
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,217,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 8,987,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,756,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

POC(Point of Care) 감염증 검사 시장 규모는 향후 몇 년 동안 빠르게 성장하여 2029년까지 13.7%의 CAGR로 80억 2,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장의 원동력은 신속한 진단에 대한 수요 증가, 전염병의 유행 증가, 원격지 및 자원이 부족한 지역에서의 채택 확대, 분산형 의료로의 전환, 정부 지원책 및 자금 지원 등입니다. 예측 기간 동안 주요 동향으로는 분자진단학의 발전, 첨단 현장 검사 장비의 개발, 바이오 센서 및 검출 기술의 혁신, 모바일 헬스 애플리케이션의 발전, 의료 서비스 제공자와 기술 기업 간의 협력적 파트너십 등이 있습니다.

전염병 유행의 증가는 향후 POC(Point of Care) 감염증 검사 시장의 성장을 촉진할 것으로 예상됩니다. 전염병은 직접 접촉, 공기 중 비말 또는 기타 감염 경로를 통해 사람에서 사람으로 전파될 수 있는 질병을 말합니다. 이러한 질병의 발생이 증가하고 있는 것은 지역과 국가를 넘어 이동하는 사람들이 늘어나면서 감염 요인의 확산이 가속화되고 있는 것이 주요 원인입니다. 현장 진료 감염병 검사는 전염병의 발견과 진단을 신속히 하고, 적시에 치료를 가능하게 하며, 지역사회 내 감염 위험을 줄이는 데 도움이 됩니다. 예를 들어, 2024년 6월 영국 보건안전국은 2022년 40주부터 2023년 15주까지 영국의 108개 NHS 트러스트가 독감 확진으로 인한 1,681건의 중증 환자 입원을 기록했다고 보고했습니다. 이에 비해 지난 시즌에는 114개 트러스트에서 182건의 독감 입원이 발생했으며, 2022년 39주차까지 316건으로 증가했습니다. 이처럼 전염성 질환의 증가는 POC(Point of Care) 감염증 검사 시장의 성장에 박차를 가하고 있습니다.

POC(Point of Care) 감염증 검사 시장의 기업들은 검사 정확도 향상, 결과 도출 시간 단축, 환자 결과 개선을 위해 독자적인 미세 유체 기술과 같은 혁신적인 기술을 점점 더 많이 통합하고 있습니다. 미세유체 기술에는 소량의 유체를 마이크로 규모로 조작하는 특수 시스템이 포함되어 있어 신속하고 정확하며 비용 효율적인 분석이 가능합니다. 이 기술은 샘플 수집, 분석 및 결과 출력을 통합하여 현장에서 신속하게 병원균을 검출할 수 있게함으로써 POC(Point-of-Care) 감염 검사에 이점을 제공하고, 집중적인 실험실 검사 없이도 진단의 속도와 접근성을 향상시킬 수 있습니다. 예를 들어, 일본에 본사를 둔 진단약제 회사인 시스멕스(Sysmex Corporation)는 2023년 6월 유럽에서 항균제 감수성을 직접 검출하는 최초의 현장진단 솔루션인 PA-100 AST 시스템을 출시하였습니다. 이 시스템은 첨단 미세유체 기술을 통해 세균 감염을 신속하게 확인하고 항균제 효과를 평가할 수 있어 기존 방식에 비해 처리 시간을 크게 단축할 수 있습니다. 컴팩트한 데스크톱 크기의 분석기와 일회용 샘플 카트리지가 포함되어 있어 일차 진료소와 같이 환자와 가까운 환경에서 사용하기에 적합합니다. 이 시스템은 보다 신속하고 정확한 항균제 치료 결정을 촉진하도록 설계되었으며, 진단 효율을 향상시킴으로써 전 세계 항균제 내성 퇴치에 기여할 수 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

ksm
영문 목차

영문목차

Point of care (POC) infectious disease testing involves diagnostic tests conducted at or near the location of patient care, such as in hospitals, clinics, doctor's offices, or even at home. These tests are designed to quickly and accurately detect infectious diseases, providing immediate results to support timely treatment decisions. POC tests are typically easy to use, require minimal equipment, and deliver results within minutes to hours, making them particularly useful when fast diagnosis is essential.

The primary product categories in point of care infectious disease testing are kits and reagents, as well as instruments. Kits and reagents consist of pre-prepared components used in point-of-care diagnostics to rapidly identify infectious agents through reactions with patient samples. Common technologies include lateral flow immunoassay, agglutination tests, flow-through tests, immunoconcentration assays, and molecular diagnostics, among others. The diseases tested for include human immunodeficiency virus (HIV), Clostridium difficile, hepatitis B virus, pneumonia or streptococcus-related infections, respiratory syncytial virus, human papillomavirus, influenza, and more. Point-of-care testing is utilized by various end-users, including hospitals, diagnostic centers, research and academic institutions, homecare settings, and others.

The point of care infectious disease testing market research report is one of a series of new reports from The Business Research Company that provides point of care infectious disease testing market statistics, including the point of care infectious disease testing industry global market size, regional shares, competitors with the point of care infectious disease testing market share, detailed point of care infectious disease testing market segments, market trends, and opportunities, and any further data you may need to thrive in the point of care infectious disease testing industry. This point of care infectious disease testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The point of care infectious disease testing market size has grown rapidly in recent years. It will grow from $4.21 billion in 2024 to $4.79 billion in 2025 at a compound annual growth rate (CAGR) of 14.0%. The growth observed in the past can be attributed to the rising demand for rapid diagnostic solutions, the increasing incidence of infectious diseases, greater healthcare awareness, higher healthcare expenditure, and the growing adoption of home care and self-testing solutions.

The point of care infectious disease testing market size is expected to see rapid growth in the next few years. It will grow to $8.02 billion in 2029 at a compound annual growth rate (CAGR) of 13.7%. The growth expected in the forecast period is driven by the increasing demand for rapid diagnostics, the rising prevalence of infectious diseases, greater adoption in remote and resource-constrained areas, a shift toward decentralized healthcare, and supportive government initiatives and funding. Key trends in the forecast period include advancements in molecular diagnostics, development of advanced point-of-care testing devices, innovations in biosensors and detection technologies, progress in mobile health applications, and collaborative partnerships between healthcare providers and technology companies.

The increasing prevalence of contagious diseases is expected to drive the growth of the point-of-care infectious disease testing market in the future. A contagious disease is one that can spread from person to person through direct contact, airborne droplets, or other transmission methods. The growing incidence of such diseases is largely due to increased human mobility, as more people move across regions and countries, which accelerates the spread of infectious agents. Point-of-care infectious disease testing helps speed up the detection and diagnosis of contagious diseases, allowing for timely treatment and reducing the risk of transmission within communities. For example, in June 2024, the UK Health Security Agency reported that from week 40 of 2022 to week 15 of 2023, 108 NHS trusts in England recorded 1,681 critical care admissions due to confirmed influenza. In comparison, the previous flu season saw only 182 admissions across 114 trusts, which increased to 316 by week 39 of 2022. Thus, the rising number of contagious diseases is fueling the growth of the point-of-care infectious disease testing market.

Companies in the point-of-care infectious disease testing market are increasingly integrating innovative technologies such as proprietary microfluidic technology to improve test accuracy, reduce time-to-results, and enhance patient outcomes. Microfluidic technology involves specialized systems that manipulate small fluid volumes at the microscale, enabling fast, precise, and cost-effective analysis. This technology benefits point-of-care infectious disease testing by allowing rapid, on-site pathogen detection with integrated sample collection, analysis, and result output, thus enhancing diagnostic speed and accessibility without requiring centralized laboratory testing. For instance, in June 2023, Sysmex Corporation, a diagnostics company based in Japan, launched the PA-100 AST System in Europe, the first point-of-care solution for directly detecting antimicrobial susceptibility. Using advanced microfluidic technology, this system enables quick identification of bacterial infections and assessment of antimicrobial effectiveness, significantly reducing processing times compared to conventional methods. It includes a compact, desktop-sized analyzer and single-use sample cartridges, making it ideal for near-patient settings such as primary care clinics. Designed to facilitate faster and more accurate antimicrobial therapy decisions, this system contributes to the global fight against antimicrobial resistance by improving diagnostic efficiency.

In July 2024, F. Hoffmann-La Roche AG, a Swiss pharmaceutical company, acquired LumiraDx's point-of-care technology for $295 million. This acquisition allows Roche to expand access to decentralized diagnostic testing by incorporating LumiraDx's versatile point-of-care platform into its diagnostics portfolio. This integration aims to provide timely and actionable results across primary care and underserved healthcare settings. LumiraDx, a U.S.-based medical equipment manufacturer, specializes in point-of-care infectious disease testing.

Major players in the point of care infectious disease testing market are Cardinal Health, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Becton Dickinson and Company, Quest Diagnostics Incorporated, bioMerieux Societe Anonyme, QuidelOrtho Corporation, Bio-Rad Laboratories Inc., DiaSorin Societa per Azioni, Danaher Corporation, Cue Health Inc., Nova Biomedical Corporation, Seegene Incorporated, Biosynex Societe Anonyme, Trivitron Healthcare Private Limited, EKF Diagnostics Holdings plc, Trinity Biotech Public Limited Company, and bioLytical Laboratories Inc.

North America was the largest region in the point of care infectious disease testing market in 2024. Asia-Pacific is expected to be the Fastest-Growing region in the forecast period. The regions covered in point-of-care infectious disease testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the point-of-care infectious disease testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The point-of-care infectious disease testing market consists of revenues earned by entities by providing services such as rapid diagnostic testing, disease screening, and onsite sample analysis for infectious conditions. The market value includes the value of related goods sold by the service provider or included within the service offering. The point-of-care infectious disease testing market also includes sales of handheld analyzers, lateral flow assays, molecular testing devices, and related consumables used for the immediate detection of infectious diseases. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Point Of Care Infectious Disease Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on point of care infectious disease testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for point of care infectious disease testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The point of care infectious disease testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Point Of Care Infectious Disease Testing Market Characteristics

3. Point Of Care Infectious Disease Testing Market Trends And Strategies

4. Point Of Care Infectious Disease Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Point Of Care Infectious Disease Testing Growth Analysis And Strategic Analysis Framework

6. Point Of Care Infectious Disease Testing Market Segmentation

7. Point Of Care Infectious Disease Testing Market Regional And Country Analysis

8. Asia-Pacific Point Of Care Infectious Disease Testing Market

9. China Point Of Care Infectious Disease Testing Market

10. India Point Of Care Infectious Disease Testing Market

11. Japan Point Of Care Infectious Disease Testing Market

12. Australia Point Of Care Infectious Disease Testing Market

13. Indonesia Point Of Care Infectious Disease Testing Market

14. South Korea Point Of Care Infectious Disease Testing Market

15. Western Europe Point Of Care Infectious Disease Testing Market

16. UK Point Of Care Infectious Disease Testing Market

17. Germany Point Of Care Infectious Disease Testing Market

18. France Point Of Care Infectious Disease Testing Market

19. Italy Point Of Care Infectious Disease Testing Market

20. Spain Point Of Care Infectious Disease Testing Market

21. Eastern Europe Point Of Care Infectious Disease Testing Market

22. Russia Point Of Care Infectious Disease Testing Market

23. North America Point Of Care Infectious Disease Testing Market

24. USA Point Of Care Infectious Disease Testing Market

25. Canada Point Of Care Infectious Disease Testing Market

26. South America Point Of Care Infectious Disease Testing Market

27. Brazil Point Of Care Infectious Disease Testing Market

28. Middle East Point Of Care Infectious Disease Testing Market

29. Africa Point Of Care Infectious Disease Testing Market

30. Point Of Care Infectious Disease Testing Market Competitive Landscape And Company Profiles

31. Point Of Care Infectious Disease Testing Market Other Major And Innovative Companies

32. Global Point Of Care Infectious Disease Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Point Of Care Infectious Disease Testing Market

34. Recent Developments In The Point Of Care Infectious Disease Testing Market

35. Point Of Care Infectious Disease Testing Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기